Referências

1. Aan Het Rot M., Collins K.A., Murrough J.W., Et al., Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression, Biol Psychiatry, 67, pp. 139-145, (2010)
2. Agid Y., Buzsaki G., Diamond D.M., Et al., How can drug discovery for psychiatric disorders be improved, Nat Rev Drug Discov, 6, pp. 189-201, (2007)
3. Azbill R.D., Mu X., Springer J.E., Riluzole increases high-affinity glutamate uptake in rat spinal cord synaptosomes, Brain Res, 871, pp. 175-180, (2000)
4. Banasr M., Duman R.S., Glial loss in the prefrontal cortex is sufficient to induce depressive-like behaviors, Biol Psychiatry, 64, pp. 863-870, (2008)
5. Banasr M., Chowdhury G.M., Terwilliger R., Et al., Glial pathology in an animal model of depression: Reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole, Mol Psychiatry, 15, pp. 501-511, (2010)
6. Barbon A., Popoli M., La Via L., Et al., Regulation of editing and expression of glutamate alpha-amino-propionic-acid (AMPA)/kainate receptors by antidepressant drugs, Biol Psychiatry, 59, pp. 713-720, (2006)
7. Barria A., Malinow R., Subunit-specific NMDA receptor trafficking to synapses, Neuron, 35, pp. 345-353, (2002)
8. Beneyto M., Meador-Woodruff J.H., Lamina-specific abnormalities of AMPA receptor trafficking and signaling molecule transcripts in the prefrontal cortex in schizophrenia, Synapse, 60, pp. 585-598, (2006)
9. Beneyto M., Kristiansen L.V., Oni-Orisan A., McCullumsmith R.E., Meador-Woodruff J.H., Abnormal glutamate receptor expression in the medial temporal lobe in schizophrenia and mood disorders, Neuropsychopharmacology, 32, pp. 1888-1902, (2007)
10. Berman R.M., Cappiello A., Anand A., Et al., Antidepressant effects of ketamine in depressed patients, Biol Psychiatry, 47, pp. 351-354, (2000)
11. Bhagwagar Z., Wylezinska M., Jezzard P., Et al., Reduction in occipital cortex gamma-aminobutyric acid concentrations in medication-free recovered unipolar depressed and bipolar subjects, Biol Psychiatry, 61, pp. 806-812, (2007)
12. Black M.D., Therapeutic potential of positive AMPA modulators and their relationship to AMPA receptor subunits. A review of preclinical data, Psychopharmacology (Berl), 179, pp. 154-163, (2005)
13. Bleakman D., Lodge D., Neuropharmacology of AMPA and kainate receptors, Neuropharmacology, 37, pp. 1187-1204, (1998)
14. Borza I., Bozo E., Barta-Szalai G., Et al., Selective NR1/2B N-methyl-d-aspartate receptor antagonists among indole-2-carboxamides and benzimidazole-2-carboxamides, J Med Chem, 50, pp. 901-914, (2007)
15. Boyce-Rustay J.M., Holmes A., Genetic inactivation of the NMDA receptor NR2A subunit has anxiolytic-and antidepressant-like effects in mice, Neuropsychopharmacology, 31, pp. 2405-2414, (2006)
16. Chaki S., Yoshikawa R., Hirota S., Et al., MGS0039: A potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity, Neuropharmacology, 46, pp. 457-467, (2004)
17. Chen C.H., Ridler K., Suckling J., Et al., Brain imaging correlates of depressive symptom severity and predictors of symptom improvement after antidepressant treatment, Biol Psychiatry, 62, pp. 407-414, (2007)
18. Choudary P.V., Molnar M., Evans S.J., Et al., Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression, Proc Natl Acad Sci USA, 102, pp. 15653-15658, (2005)
19. Chourbaji S., Vogt M.A., Fumagalli F., Et al., AMPA receptor subunit 1 (GluR-A) knockout mice model the glutamate hypothesis of depression, FASEB J, 22, pp. 3129-3134, (2008)
20. Chowdhury G.M., Banasr M., de Graaf R.A., Et al., Chronic riluzole treatment increases glucose metabolism in rat prefrontal cortex and hippocampus, J Cereb Blood Flow Metab, 28, pp. 1892-1897, (2008)
21. Clinton S.M., Meador-Woodruff J.H., Abnormalities of the NMDA receptor and associated intracellular molecules in the thalamus in schizophrenia and bipolar disorder, Neuropsychopharmacology, 29, pp. 1353-1362, (2004)
22. Collingridge G.L., Bliss T.V., Memories of NMDA receptors and LTP, Trends Neurosci, 18, pp. 54-56, (1995)
23. Coric V., Taskiran S., Pittenger C., Et al., Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: An open-label trial, Biol Psychiatry, 58, pp. 424-428, (2005)
24. Cosford N.D., Tehrani L., Roppe J., Et al., 3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-pyridine: A potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activity, J Med Chem, 46, pp. 204-206, (2003)
25. Cryan J.F., Kelly P.H., Neijt H.C., Et al., Antidepressant and anxiolytic-like effects in mice lacking the group III metabotropic glutamate receptor mGluR7, Eur J Neurosci, 17, pp. 2409-2417, (2003)
26. Cull-Candy S., Brickley S., Farrant M., NMDA receptor subunits: Diversity, development and disease, Curr Opin Neurobiol, 11, pp. 327-335, (2001)
27. Dagci T., Yilmaz O., Taskiran D., Peker G., Neuroprotective agents: Is effective on toxicity in glial cells, Cell Mol Neurobiol, 27, pp. 171-177, (2007)
28. Danbolt N.C., Glutamate uptake, Prog Neurobiol, 65, pp. 1-105, (2001)
29. Debono M.W., Le Guern J., Canton T., Doble A., Pradier L., Inhibition by riluzole of electrophysiological responses mediated by rat kainate and NMDA receptors expressed in Xenopus oocytes, Eur J Pharmacol, 235, pp. 283-289, (1993)
30. Devon R.S., Anderson S., Teague P.W., Et al., Identification of polymorphisms within Disrupted in Schizophrenia 1 and Disrupted in Schizophrenia 2, and an investigation of their association with schizophrenia and bipolar affective disorder, Psychiatr Genet, 11, pp. 71-78, (2001)
31. Diaz-Granados N., Ibrahim L., Brutsche N.E., Et al., A randomized add-on trial of an N-methyl-d-aspartate antagonist in treatment-resistant bipolar depression, Arch Gen Psychiatry, 67, pp. 793-802, (2010)
32. Diaz-Granados N., Ibrahim L.A., Brutsche N.E., Et al., Rapid resolution of suicidal ideation after a single infusion of an N-methyl-d-aspartate antagonist in patients with treatment-resistant major depressive disorder, J Clin Psychiatry, (2010)
33. Dingledine R., Borges K., Bowie D., Traynelis S.F., The glutamate receptor ion channels, Pharmacol Rev, 51, pp. 7-61, (1999)
34. Du J., Gray N.A., Falke C.A., Et al., Modulation of synaptic plasticity by antimanic agents: The role of AMPA glutamate receptor subunit 1 synaptic expression, J Neurosci, 24, pp. 6578-6589, (2004)
35. Du J., Suzuki K., Wei Y., Et al., The anticonvulsants lamotrigine, riluzole, and valproate differentially regulate AMPA receptor membrane localization: Relationship to clinical effects in mood disorders, Neuropsychopharmacology, 32, pp. 793-802, (2007)
36. Entsuah A.R., Huang H., Thase M.E., Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo, J Clin Psychiatry, 62, pp. 869-877, (2001)
37. Fagiolini A., Kupfer D.J., Masalehdan A., Et al., Functional impairment in the remission phase of bipolar disorder, Bipolar Disord, 7, pp. 281-285, (2005)
38. Frizzo M.E., Dall'Onder L.P., Dalcin K.B., Souza D.O., Riluzole enhances glutamate uptake in rat astrocyte cultures, Cell Mol Neurobiol, 24, pp. 123-128, (2004)
39. Fumagalli E., Funicello M., Rauen T., Gobbi M., Mennini T., Riluzole enhances the activity of glutamate transporters GLAST, GLT1 and EAAC1, Eur J Pharmacol, 578, pp. 171-176, (2008)
40. Gasparini F., Bruno V., Battaglia G., Et al., (R,S)-4-Phosphonophenylglycine, a potent and selective group III metabotropic glutamate receptor agonist, is anticonvulsive and neuroprotective in vivo, J Pharmacol Exp Ther, 289, pp. 1678-1687, (1999)
41. Goforth H.W., Holsinger T., Rapid relief of severe major depressive disorder by use of preoperative ketamine and electroconvulsive therapy, J ECT, 23, pp. 23-25, (2007)
42. Hardingham G.E., Pro-survival signalling from the NMDA receptor, Biochem Soc Trans, 34, pp. 936-938, (2006)
43. Hashimoto K., Sawa A., Iyo M., Increased levels of glutamate in brains from patients with mood disorders, Biol Psychiatry, 62, pp. 1310-1316, (2007)
44. Hashimoto R., Hough C., Nakazawa T., Yamamoto T., Chuang D.M., Lithium protection against glutamate excitotoxicity in rat cerebral cortical neurons: Involvement of NMDA receptor inhibition possibly by decreasing NR2B tyrosine phosphorylation, J Neurochem, 80, pp. 589-597, (2002)
45. Hasler G., van der Veen J.W., Tumonis T., Et al., Reduced prefrontal glutamate/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy, Arch Gen Psychiatry, 64, pp. 193-200, (2007)
46. Hassel B., Iversen E.G., Gjerstad L., Tauboll E., Up-regulation of hippocampal glutamate transport during chronic treatment with sodium valproate, J Neurochem, 77, pp. 1285-1292, (2001)
47. Hollmann M., Heinemann S., Cloned glutamate receptors, Annu Rev Neurosci, 17, pp. 31-108, (1994)
48. Huettner J.E., Kainate receptors and synaptic transmission, Prog Neurobiol, 70, pp. 387-407, (2003)
49. Insel T.R., Scolnick E.M., Cure therapeutics and strategic prevention: Raising the bar for mental health research, Mol Psychiatry, 11, pp. 11-17, (2006)
50. Itokawa M., Yamada K., Iwayama-Shigeno Y., Et al., Genetic analysis of a functional GRIN2A promoter (GT)n repeat in bipolar disorder pedigrees in humans, Neurosci Lett, 345, pp. 53-56, (2003)
51. Jabaudon D., Shimamoto K., Yasuda-Kamatani Y., Et al., Inhibition of uptake unmasks rapid extracellular turnover of glutamate of nonvesicular origin, Proc Natl Acad Sci USA, 96, pp. 8733-8738, (1999)
52. Judd L.L., Akiskal H.S., Schettler P.J., Et al., The long-term natural history of the weekly symptomatic status of bipolar I disorder, Arch Gen Psychiatry, 59, pp. 530-537, (2002)
53. Karasawa J., Shimazaki T., Kawashima N., Chaki S., AMPA receptor stimulation mediates the antidepressant-like effect of a group II metabotropic glutamate receptor antagonist, Brain Res, 1042, pp. 92-98, (2005)
54. Karolewicz B., Szebeni K., Gilmore T., Et al., Elevated levels of NR2A and PSD-95 in the lateral amygdala in depression, Int J Neuropsychopharmacol, 12, pp. 143-153, (2009)
55. Kasper S., McEwen B.S., Neurobiological and clinical effects of the antidepressant tianeptine, CNS Drugs, 22, pp. 15-26, (2008)
56. Kaster M.P., Raupp I., Binfare R.W., Andreatini R., Rodrigues A.L., Antidepressant-like effect of lamotrigine in the mouse forced swimming test: Evidence for the involvement of the noradrenergic system, Eur J Pharmacol, 565, pp. 119-124, (2007)
57. Katoh-Semba R., Asano T., Ueda H., Et al., Riluzole enhances expression of brain-derived neurotrophic factor with consequent proliferation of granule precursor cells in the rat hippocampus, FASEB J, 16, pp. 1328-1330, (2002)
58. Kessal K., Chessel A., Spennato G., Garcia R., Ketamine and amphetamine both enhance synaptic transmission in the amygdala-nucleus accumbens pathway but with different time-courses, Synapse, 57, pp. 61-65, (2005)
59. Kristiansen L.V., Meador-Woodruff J.H., Abnormal striatal expression of transcripts encoding NMDA interacting PSD proteins in schizophrenia, bipolar disorder and major depression, Schizophr Res, 78, pp. 87-93, (2005)
60. Krystal J.H., Petrakis I.L., Krupitsky E., Et al., NMDA receptor antagonism and the ethanol intoxication signal: From alcoholism risk to pharmacotherapy, Ann N Y Acad Sci, 1003, pp. 176-184, (2003)
61. Kudoh A., Takahira Y., Katagai H., Takazawa T., Small-dose ketamine improves the postoperative state of depressed patients, Anesth Analg, 95, pp. 114-118, (2002)
62. Laje G., Paddock S., Manji H., Et al., Genetic markers of suicidal ideation emerging during citalopram treatment of major depression, Am J Psychiatry, 164, pp. 1530-1538, (2007)
63. Langguth B., Wiegand R., Kharraz A., Et al., Pre-treatment anterior cingulate activity as a predictor of antidepressant response to repetitive transcranial magnetic stimulation (rTMS), Neuro Endocrinol Lett, 28, pp. 633-638, (2007)
64. Law A.J., Deakin J.F., Asymmetrical reductions of hippocampal NMDAR1 glutamate receptor mRNA in the psychoses, Neuroreport, 12, pp. 2971-2974, (2001)
65. Lee Y., Gaskins D., Anand A., Shekhar A., Glia mechanisms in mood regulation: A novel model of mood disorders, Psychopharmacology (Berl), 191, pp. 55-65, (2007)
66. Li X., Need A.B., Baez M., Witkin J.M., Metabotropic glutamate 5 receptor antagonism is associated with antidepressant-like effects in mice, J Pharmacol Exp Ther, 319, pp. 254-259, (2006)
67. Liebrenz M., Borgeat A., Leisinger R., Stohler R., Intravenous ketamine therapy in a patient with a treatment-resistant major depression, Swiss Med Wkly, 137, pp. 234-236, (2007)
68. Lourenco Da Silva A., Hoffmann A., Dietrich M.O., Et al., Effect of riluzole on MK-801 and amphetamine-induced hyperlocomotion, Neuropsychobiology, 48, pp. 27-30, (2003)
69. Lynch G., AMPA receptor modulators as cognitive enhancers, Curr Opin Pharmacol, 4, pp. 4-11, (2004)
70. Machado-Vieira R., Manji H.K., Zarate C.A., The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders, Neuroscientist, 15, pp. 525-539, (2009)
71. Machado-Vieira R., Salvadore G., Ibrahim L.A., Diaz-Granados N., Zarate C.A., Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders, Curr Pharm Des, 15, pp. 1595-1611, (2009)
72. Machado-Vieira R., Yuan P., Brutsche N., Et al., Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-d-aspartate antagonist, J Clin Psychiatry, 70, pp. 1662-1666, (2009)
73. Maeng S., Zarate C.A., Du J., Et al., Cellular mechanisms underlying the antidepressant effects of ketamine: Role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors, Biol Psychiatry, 63, pp. 349-352, (2008)
74. Magnusson K.R., Nelson S.E., Young A.B., Age-related changes in the protein expression of subunits of the NMDA receptor, Brain Res Mol Brain Res, 99, pp. 40-45, (2002)
75. Maiese K., Vincent A., Lin S.H., Shaw T., Group I and group III metabotropic glutamate receptor subtypes provide enhanced neuroprotection, J Neurosci Res, 62, pp. 257-272, (2000)
76. Manji H.K., Zarate C.A., Molecular and cellular mechanisms underlying mood stabilization in bipolar disorder: Implications for the development of improved therapeutics, Mol Psychiatry, 7, pp. S1-S7, (2002)
77. Marti S.B., Cichon S., Propping P., Nothen M., Metabotropic glutamate receptor 3 (GRM3) gene variation is not associated with schizophrenia or bipolar affective disorder in the German population, Am J Med Genet, 114, pp. 46-50, (2002)
78. Martucci L., Wong A.H., De Luca V., Et al., N-methyl-d-aspartate receptor NR2B subunit gene GRIN2B in schizophrenia and bipolar disorder: Polymorphisms and mRNA levels, Schizophr Res, 84, pp. 214-221, (2006)
79. Mathew S.J., Amiel J.M., Coplan J.D., Et al., Open-label trial of riluzole in generalized anxiety disorder, Am J Psychiatry, 162, pp. 2379-2381, (2005)
80. Mayberg H.S., Brannan S.K., Mahurin R.K., Et al., Cingulate function in depression: A potential predictor of treatment response, Neuroreport, 8, pp. 1057-1061, (1997)
81. McCormick L.M., Boles Ponto L.L., Pierson R.K., Et al., Metabolic correlates of antidepressant and antipsychotic response in patients with psychotic depression undergoing electroconvulsive therapy, J ECT, 23, pp. 265-273, (2007)
82. McCullumsmith R.E., Meador-Woodruff J.H., Striatal excitatory amino acid transporter transcript expression in schizophrenia, bipolar disorder, and major depressive disorder, Neuropsychopharmacology, 26, pp. 368-375, (2002)
83. McCullumsmith R.E., Kristiansen L.V., Beneyto M., Et al., Decreased NR1, NR2A, and SAP102 transcript expression in the hippocampus in bipolar disorder, Brain Res, 1127, pp. 108-118, (2007)
84. McElroy S.L., Zarate C.A., Cookson J., Et al., A 52-week, open-label continuation study of lamotrigine in the treatment of bipolar depression, J Clin Psychiatry, 65, pp. 204-210, (2004)
85. Meador-Woodruff J.H., Hogg A.J., Smith R.E., Striatal ionotropic glutamate receptor expression in schizophrenia, bipolar disorder, and major depressive disorder, Brain Res Bull, 55, pp. 631-640, (2001)
86. Menke A., Lucae S., Kloiber S., Et al., Genetic markers within glutamate receptors associated with antidepressant treatment-emergent suicidal ideation, Am J Psychiatry, 165, pp. 917-918, (2008)
87. Mineur Y.S., Picciotto M.R., Sanacora G., Antidepressant-like effects of ceftriaxone in male C57BL/6J mice, Biol Psychiatry, 61, pp. 250-252, (2007)
88. Miu P., Jarvie K.R., Radhakrishnan V., Et al., Novel AMPA receptor potentiators LY392098 and LY404187: Effects on recombinant human AMPA receptors in vitro, Neuropharmacology, 40, pp. 976-983, (2001)
89. Mizuta I., Ohta M., Ohta K., Et al., Riluzole stimulates nerve growth factor, brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor synthesis in cultured mouse astrocytes, Neurosci Lett, 310, pp. 117-120, (2001)
90. Moghaddam B., Adams B., Verma A., Daly D., Activation of glutamatergic neurotransmission by ketamine: A novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex, J Neurosci, 17, pp. 2921-2927, (1997)
91. Moryl E., Danysz W., Quack G., Potential antidepressive properties of amantadine, memantine and bifemelane, Pharmacol Toxicol, 72, pp. 394-397, (1993)
92. Moutsimilli L., Farley S., Dumas S., Et al., Selective cortical VGLUT1 increase as a marker for antidepressant activity, Neuropharmacology, 49, pp. 890-900, (2005)
93. Mundo E., Tharmalingham S., Neves-Pereira M., Et al., Evidence that the N-methyl-d-aspartate subunit 1 receptor gene (GRIN1) confers susceptibility to bipolar disorder, Mol Psychiatry, 8, pp. 241-245, (2003)
94. Murray C.J., Lopez A.D., Evidence-based health policy-Lessons from the Global Burden of Disease Study, Science, 274, pp. 740-743, (1996)
95. Nakanishi S., Molecular diversity of glutamate receptors and implications for brain function, Science, 258, pp. 597-603, (1992)
96. Nowak G., Trullas R., Layer R.T., Skolnick P., Paul I.A., Adaptive changes in the N-methyl-d-aspartate receptor complex after chronic treatment with imipramine and 1-aminocyclopropanecarboxylic acid, J Pharmacol Exp Ther, 265, pp. 1380-1386, (1993)
97. Nudmamud-Thanoi S., Reynolds G.P., The NR1 subunit of the glutamate/NMDA receptor in the superior temporal cortex in schizophrenia and affective disorders, Neurosci Lett, 372, pp. 173-177, (2004)
98. O'Neill M.J., Bleakman D., Zimmerman D.M., Nisenbaum E.S., AMPA receptor potentiators for the treatment of CNS disorders, Curr Drug Targets CNS Neurol Disord, 3, pp. 181-194, (2004)
99. O'Shea R.D., Roles and regulation of glutamate transporters in the central nervous system, Clin Exp Pharmacol Physiol, 29, pp. 1018-1023, (2002)
100. Oliet S.H., Piet R., Poulain D.A., Control of glutamate clearance and synaptic efficacy by glial coverage of neurons, Science, 292, pp. 923-926, (2001)
101. Ostroff R., Gonzales M., Sanacora G., Antidepressant effect of ketamine during ECT, Am J Psychiatry, 162, pp. 1385-1386, (2005)
102. Paddock S., Laje G., Charney D., Et al., Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort, Am J Psychiatry, 164, pp. 1181-1188, (2007)
103. Palucha A., Pilc A., Metabotropic glutamate receptor ligands as possible anxiolytic and antidepressant drugs, Pharmacol Ther, 115, pp. 116-147, (2007)
104. Palucha A., Tatarczynska E., Branski P., Et al., Group III mGlu receptor agonists produce anxiolytic-and antidepressant-like effects after central administration in rats, Neuropharmacology, 46, pp. 151-159, (2004)
105. Palucha A., Branski P., Klak K., Sowa M., Chronic imipramine treatment reduces inhibitory prop erties of group II mGlu receptors without affecting their density or affinity, Pharmacol Rep, 59, pp. 525-530, (2007)
106. Papp M., Moryl E., Antidepressant activity of non-competitive and competitive NMDA receptor antagonists in a chronic mild stress model of depression, Eur J Pharmacol, 263, pp. 1-7, (1994)
107. Paul I.A., Skolnick P., Glutamate and depression: Clinical and preclinical studies, Ann N Y Acad Sci, 1003, pp. 250-272, (2003)
108. Paul I.A., Nowak G., Layer R.T., Popik P., Skolnick P., Adaptation of the N-methyl-d-aspartate receptor complex following chronic antidepressant treatments, J Pharmacol Exp Ther, 269, pp. 95-102, (1994)
109. Petrakis I.L., Limoncelli D., Gueorguieva R., Et al., Altered NMDA glutamate receptor antagonist response in individuals with a family vulnerability to alcoholism, Am J Psychiatry, 161, pp. 1776-1782, (2004)
110. Petrenko A.B., Yamakura T., Fujiwara N., Et al., Reduced sensitivity to ketamine and pentobarbital in mice lacking the N-methyl-d-aspartate receptor GluRepsilon1 subunit, Anesth Analg, 99, pp. 1136-1140, (2004)
111. Phelps L.E., Brutsche N., Moral J.R., Et al., Family history of alcohol dependence and initial antidepressant response to an N-methyl-d-aspartate antagonist, Biol Psychiatry, 65, pp. 181-184, (2009)
112. Pickard B.S., Malloy M.P., Christoforou A., Et al., Cytogenetic and genetic evidence supports a role for the kainate-type glutamate receptor gene, GRIK4, in schizophrenia and bipolar disorder, Mol Psychiatry, 11, pp. 847-857, (2006)
113. Pizzagalli D., Pascual-Marqui R.D., Nitschke J.B., Et al., Anterior cingulate activity as a predictor of degree of treatment response in major depression: Evidence from brain electrical tomography analysis, Am J Psychiatry, 158, pp. 405-415, (2001)
114. Porter R.H., Jaeschke G., Spooren W., Et al., Fenobam: A clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity, J Pharmacol Exp Ther, 315, pp. 711-721, (2005)
115. Preskorn S.H., Baker B., Kolluri S., Et al., An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-d-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder, J Clin Psychopharmacol, 28, pp. 631-637, (2008)
116. Prica C., Hascoet M., Bourin M., Antidepressant-like effect of lamotrigine is reversed by veratrine: A possible role of sodium channels in bipolar depression, Behav Brain Res, 191, pp. 49-54, (2008)
117. Price R.B., Nock M.K., Charney D., Mathew S.J., Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression, Biol Psychiatry, 66, pp. 522-529, (2009)
118. Quiroz J.A., Gould T.D., Manji H.K., Molecular effects of lithium, Mol Interv, 4, pp. 259-272, (2004)
119. Rogawski M.A., Diverse mechanisms of antiepileptic drugs in the development pipeline, Epilepsy Res, 69, pp. 273-294, (2006)
120. Sah P., Lopez De Armentia M., Excitatory synaptic transmission in the lateral and central amygdala, Ann N Y Acad Sci, 985, pp. 67-77, (2003)
121. Sajatovic M., Valenstein M., Blow F.C., Ganoczy D., Ignacio R.V., Treatment adherence with antipsychotic medications in bipolar disorder, Bipolar Disord, 8, pp. 232-241, (2006)
122. Salvadore G., Cornwell B.R., Colon-Rosario V., Et al., Increased anterior cingulate cortical activity in response to fearful faces: A neurophysiological biomarker that predicts rapid antidepressant response to ketamine, Biol Psychiatry, 65, pp. 289-295, (2009)
123. Sanacora G., Gueorguieva R., Epperson C.N., Et al., Subtype-specific alterations of GABA and glutamate in major depression, Arch Gen Psychiatry, 61, pp. 705-713, (2004)
124. Sanacora G., Kendell S.F., Levin Y., Et al., Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms, Biol Psychiatry, 61, pp. 822-825, (2007)
125. Sanacora G., Zarate C.A., Krystal J.H., Manji H.K., Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders, Nat Rev Drug Discov, 7, pp. 426-437, (2008)
126. Saxena S., Brody A.L., Ho M.L., Et al., Differential brain metabolic predictors of response to paroxetine in obsessive-compulsive disorder versus major depression, Am J Psychiatry, 160, pp. 522-532, (2003)
127. Scarr E., Pavey G., Sundram S., MacKinnon A., Dean B., Decreased hippocampal NMDA, but not kainate or AMPA receptors in bipolar disorder, Bipolar Disord, 5, pp. 257-264, (2003)
128. Schiffer H.H., Heinemann S.F., Association of the human kainate receptor GluR7 gene (GRIK3) with recurrent major depressive disorder, Am J Med Genet B Neuropsychiatr Genet, 144B, pp. 20-26, (2007)
129. Schildkraut J.J., The catecholamine hypothesis of affective disorders: A review of supporting evidence, Am J Psychiatry, 122, pp. 509-522, (1965)
130. Schoepp D.D., Wright R.A., Levine L.R., Gaydos B., Potter W.Z., LY354740, an mGlu2/3 receptor agonist as a novel approach to treat anxiety/stress, Stress, 6, pp. 189-197, (2003)
131. Shaltiel G., Maeng S., Malkesman O., Et al., Evidence for the involvement of the kainate receptor subunit GluR6 (GRIK2) in mediating behavioral displays related to behavioral symptoms of mania, Mol Psychiatry, 13, pp. 858-872, (2008)
132. Sheng M., Sala C., PDZ domains and the organization of supramolecular complexes, Annu Rev Neurosci, 24, pp. 1-29, (2001)
133. Skolnick P., Layer R.T., Popik P., Et al., Adaptation of N-methyl-d-aspartate (NMDA) receptors following antidepressant treatment: Implications for the pharmacotherapy of depression, Pharmacopsychiatry, 29, pp. 23-26, (1996)
134. Song I., Kamboj S., Xia J., Et al., Interaction of the N-ethylmaleimide-sensitive factor with AMPA receptors, Neuron, 21, pp. 393-400, (1998)
135. Soriano F.X., Hardingham G.E., Compartmentalized NMDA receptor signalling to survival and death, J Physiol, 584, pp. 381-387, (2007)
136. Suetake-Koga S., Shimazaki T., Takamori K., Et al., In vitro and antinociceptive profile of HON0001, an orally active NMDA receptor NR2B subunit antagonist, Pharmacol Biochem Behav, 84, pp. 134-141, (2006)
137. Svenningsson P., Tzavara E.T., Witkin J.M., Et al., Involvement of striatal and extrastriatal DARPP-32 in biochemical and behavioral effects of fluoxetine (Prozac), Proc Natl Acad Sci USA, 99, pp. 3182-3187, (2002)
138. Svenningsson P., Bateup H., Qi H., Et al., Involvement of AMPA receptor phosphorylation in antidepressant actions with special reference to tianeptine, Eur J Neurosci, 26, pp. 3509-3517, (2007)
139. Takamori S., VGLUTs: 'Exciting' times for glutamatergic research, Neurosci Res, 55, pp. 343-351, (2006)
140. Teng C.T., Demetrio F.N., Memantine may acutely improve cognition and have a mood stabilizing effect in treatment-resistant bipolar disorder, Rev Bras Psiquiatr, 28, pp. 252-254, (2006)
141. Thase M.E., Haight B.R., Richard N., Et al., Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: A meta-analysis of original data from 7 randomized controlled trials, J Clin Psychiatry, 66, pp. 974-981, (2005)
142. Thompson C.M., Davis E., Carrigan C.N., Et al., Inhibitor of the glutamate vesicular transporter (VGLUT), Curr Med Chem, 12, pp. 2041-2056, (2005)
143. Tohen M., Strakowski S.M., Zarate C., Et al., The McLean-Harvard first-episode project: 6-Month symptomatic and functional outcome in affective and nonaffective psychosis, Biol Psychiatry, 48, pp. 467-476, (2000)
144. Tordera R.M., Pei Q., Sharp T., Evidence for increased expression of the vesicular glutamate transporter, VGLUT1, by a course of antidepressant treatment, J Neurochem, 94, pp. 875-883, (2005)
145. Tordera R.M., Totterdell S., Wojcik S.M., Et al., Enhanced anxiety, depressive-like behaviour and impaired recognition memory in mice with reduced expression of the vesicular glutamate transporter 1 (VGLUT1), Eur J Neurosci, 25, pp. 281-290, (2007)
146. Toro C., Deakin J.F., NMDA receptor subunit NRI and postsynaptic protein PSD-95 in hippocampus and orbitofrontal cortex in schizophrenia and mood disorder, Schizophr Res, 80, pp. 323-330, (2005)
147. Trivedi M.H., Rush A.J., Wisniewski S.R., Et al., Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: Implications for clinical practice, Am J Psychiatry, 163, pp. 28-40, (2006)
148. Trullas R., Skolnick P., Functional antagonists at the NMDA receptor complex exhibit antidepressant actions, Eur J Pharmacol, 185, pp. 1-10, (1990)
149. Ueda Y., Willmore L.J., Molecular regulation of glutamate and GABA transporter proteins by valproic acid in rat hippocampus during epileptogenesis, Exp Brain Res, 133, pp. 334-339, (2000)
150. Wieronska J.M., Szewczyk B., Branski P., Palucha A., Pilc A., Antidepressant-like effect of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist in the olfactory bulbectomized rats, Amino Acids, 23, pp. 213-216, (2002)
151. Wilson G.M., Flibotte S., Chopra V., Et al., DNA copy-number analysis in bipolar disorder and schizophrenia reveals aberrations in genes involved in glutamate signaling, Hum Mol Genet, 15, pp. 743-749, (2006)
152. Witkin J.M., Marek G.J., Johnson B.G., Schoepp D.D., Metabotropic glutamate receptors in the control of mood disorders, CNS Neurol Disord Drug Targets, 6, pp. 87-100, (2007)
153. Wu J., Buchsbaum M.S., Gillin J.C., Et al., Prediction of antidepressant effects of sleep deprivation by metabolic rates in the ventral anterior cingulate and medial prefrontal cortex, Am J Psychiatry, 156, pp. 1149-1158, (1999)
154. Yildiz-Yesiloglu A., Ankerst D.P., Neurochemical alterations of the brain in bipolar disorder and their implications for pathophysiology: A systematic review of the in vivo proton magnetic resonance spectroscopy findings, Prog Neuropsychopharmacol Biol Psychiatry, 30, pp. 969-995, (2006)
155. Yoon S.J., Lyoo I.K., Haws C., Et al., Decreased glutamate/glutamine levels may mediate cytidine's efficacy in treating bipolar depression: A longitudinal proton magnetic resonance spectroscopy study, Neuropsychopharmacology, 34, pp. 1810-1818, (2009)
156. Yoshimizu T., Chaki S., Increased cell proliferation in the adult mouse hippocampus following chronic administration of group II metabotropic glutamate receptor antagonist, MGS0039, Biochem Biophys Res Commun, 315, pp. 493-496, (2004)
157. Yoshimizu T., Shimazaki T., Ito A., Chaki S., An mGluR2/3 antagonist, MGS0039, exerts antidepressant and anxiolytic effects in behavioral models in rats, Psychopharmacology (Berl), 186, pp. 587-593, (2006)
158. Zarate C.A., Quiroz J.A., Combination treatment in bipolar disorder: A review of controlled trials, Bipolar Disord, 5, pp. 217-225, (2003)
159. Zarate C.A., Tohen M., Double-blind comparison of the continued use of antipsychotic treatment versus its discontinuation in remitted manic patients, Am J Psychiatry, 161, pp. 169-171, (2004)
160. Zarate C.A., Tohen M., Narendran R., Et al., The adverse effect profile and efficacy of divalproex sodium compared with valproic acid: A pharmacoepidemiology study, J Clin Psychiatry, 60, pp. 232-236, (1999)
161. Zarate C.A., Quiroz J., Payne J., Manji H.K., Modulators of the glutamatergic system: Implications for the development of improved therapeutics in mood disorders, Psychopharmacol Bull, 36, pp. 35-83, (2002)
162. Zarate C.A., Du J., Quiroz J., Et al., Regulation of cellular plasticity cascades in the pathophysiology and treatment of mood disorders: Role of the glutamatergic system, Ann N Y Acad Sci, 1003, pp. 273-291, (2003)
163. Zarate C.A., Payne J.L., Quiroz J., Et al., An open-label trial of riluzole in patients with treatment-resistant major depression, Am J Psychiatry, 161, pp. 171-174, (2004)
164. Zarate C.A., Singh J.B., Carlson P.J., Et al., A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression, Arch Gen Psychiatry, 63, pp. 856-864, (2006)
165. Zarate C.A., Singh J.B., Quiroz J.A., Et al., A double-blind, placebo-controlled study of memantine in the treatment of major depression, Am J Psychiatry, 163, pp. 153-155, (2006)
166. Zarate C.A., Machado-Vieira R., Henter I., Et al., Glutamatergic modulators: The future of treating mood disorders, Harvard Rev Psychiatry, 18, pp. 293-303, (2010)